D
Doris Augustin
Publications - 67
Citations - 772
Doris Augustin is an academic researcher. The author has contributed to research in topics: Breast cancer & Docetaxel. The author has an hindex of 13, co-authored 64 publications receiving 599 citations.
Papers
More filters
Journal ArticleDOI
Reducing chemotherapy use in clinically high-risk, genomically low-risk pN0 and pN1 early breast cancer patients: five-year data from the prospective, randomised phase 3 West German Study Group (WSG) PlanB trial
Ulrike Nitz,Oleg Gluz,Matthias Christgen,Ronald E. Kates,Michael R. Clemens,Wolfram Malter,Benno Nuding,Bahriye Aktas,Sherko Kuemmel,Toralf Reimer,Andrea Stefek,F Lorenz-Salehi,Petra Krabisch,Marianne Just,Doris Augustin,Cornelia Liedtke,Calvin Chao,Steven Shak,Rachel Wuerstlein,Hans Kreipe,Nadia Harbeck +20 more
TL;DR: Five-year outcomes in clinically high-risk, genomically low-risk pN0-1 patients without adjuvant chemotherapy support using RS with standardised pathology for treatment decisions in HR+ HER2-negative EBC has the potential to support patient selection for genomic testing.
Journal ArticleDOI
De-escalation strategies in HER2-positive early breast cancer (EBC): final analysis of the WSG-ADAPT HER2+/HR- phase II trial: efficacy, safety, and predictive markers for 12 weeks of neoadjuvant dual blockade with trastuzumab and pertuzumab ± weekly paclitaxel.
Ulrike Nitz,O Gluz,Matthias Christgen,E-M. Grischke,Doris Augustin,Sherko Kuemmel,Michael Braun,Jochem Potenberg,A. Kohls,Katja Krauss,Andrea Stefek,Claudia Schumacher,Helmut Forstbauer,T. Reimer,Hans-Peter Fischer,Cornelia Liedtke,Rachel Wuerstlein,Johannes Schumacher,Ronald E. Kates,Hans Heinrich Kreipe,Nadia Harbeck +20 more
TL;DR: Addition of taxane monotherapy to dual HER2 blockade in a 12-week neoadjuvant setting substantially increases pCR rates in HER2+/HR- EBC compared with dual blockade alone, even within early responders to dual blockade.
Journal ArticleDOI
Final analysis of the prospective WSG-AGO EC-Doc versus FEC phase III trial in intermediate-risk (pN1) early breast cancer: efficacy and predictive value of Ki67 expression
U. Nitz,U. Nitz,Oleg Gluz,Jens Huober,Hans Kreipe,Ronald E. Kates,A. Hartmann,Ramona Erber,Michael Scholz,B. Lisboa,Svjetlana Mohrmann,Volker Möbus,Doris Augustin,G. Hoffmann,E. Weiss,S. Böhmer,R. Kreienberg,A. du Bois,D. Sattler,C Thomssen,Marion Kiechle,Fritz Jänicke,D. Wallwiener,Nadia Harbeck,Walther Kuhn +24 more
TL;DR: EC-Doc significantly improved EFS and OS versus FEC in intermediate-risk BC (1-3 LNs) within all subgroups as defined by local pathology.
Journal ArticleDOI
Prospective evaluation of prognostic factors uPA/PAI-1 in node-negative breast cancer: Phase III NNBC3-Europe trial (AGO, GBG, EORTC-PBG) comparing 6 × FEC versus 3 × FEC/3 × Docetaxel
Eva Johanna Kantelhardt,Martina Vetter,Marcus Schmidt,Corinne Veyret,Doris Augustin,Volker Hanf,Christoph Meisner,Daniela Paepke,Manfred Schmitt,Fred C.G.J. Sweep,Gunter von Minckwitz,Pierre-Marie Martin,Fritz Jaenicke,Christoph Thomssen,Nadia Harbeck +14 more
TL;DR: The international NNBC3 ("Node Negative Breast Cancer 3-Europe") trial compares biological risk assessment (UP) using invasion factors uPA/PAI-1 with a clinical-pathological algorithm (CP) and showed that inclusion of patients into a clinical phase III trial is feasible based on biological testing of fresh frozen tumor material.
Journal ArticleDOI
A randomized phase III study evaluating pegylated liposomal doxorubicin versus capecitabine as first-line therapy for metastatic breast cancer: results of the PELICAN study
Nadia Harbeck,Steffen Saupe,Elke Jäger,Marcus Schmidt,Rolf Kreienberg,Lothar Müller,Burkhard Otremba,Dirk Waldenmaier,Julia Dorn,Mathias Warm,Michael Scholz,Michael Untch,Maike de Wit,Jana Barinoff,Hans-Joachim Lück,Philipp Harter,Doris Augustin,Paul R. Harnett,Matthias W. Beckmann,Salah-Eddin Al-Batran +19 more
TL;DR: Both pegylated liposomal doxorubicin and capecitabine are effective first-line agents for MBC.